HER2-directed therapy was associated with longer overall survival (median OS 73.0 months [95% CI, 0-177.9] vs 19.0 months [95% CI, 0-41.4]; HR 0.50 [95% CI, 0.0-177.9], P = .3), although this difference did not reach statistical significance.
← all excerpts
Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience.
1
—
—